OrthoPediatrics (KIDS) Q2 FY26 earnings call: guidance and Q&A

Why is the full-year guidance only 13% growth despite strong Q2 performance and positive momentum?

Management stated the guidance reflects an appropriate level of conservatism, acknowledging business seasonality and timing-dependent revenue streams like capital equipment and international stocking distributors. They expressed confidence in achieving the guidance and potentially over-delivering.

“I think we continue to apply an appropriate level of conservatism. And as we continue to execute through the second half of the year, we'll feel more confident, obviously, in raising that in the third quarter and then hopefully again in the -- and over-delivering again in the fourth quarter.”

asked by Frederick Wise · answered by Fred Hite

How much did the super cycle contribute in Q2, and will its impact be gradual or accelerate significantly in the second half and beyond?

David Bailey explained that the super cycle's contribution is still in its early days, with more substantial impact expected over the coming quarters and years as sets are deployed and adopted. He noted that these products offer higher ASPs, margins, and faster capital return, making it a durable, multi-year growth story rather than a single inflection point.

“I'm not certain that we're going to see some major inflection point in any one given quarter, but we did start to see some growth from the super cycle products here in Q2, certainly in the second part of Q2.”

asked by Frederick Wise · answered by David Bailey

Given mid-teens implant growth despite a 9% reported decline, what is the outlook for scoliosis in H2 and 2027, and could growth exceed 20% again?

David Bailey expressed strong satisfaction with scoli implant performance, highlighting robust summer volumes. He noted that VerteGlide is already impacting revenue, and eLLi represents an even bigger future opportunity. These new technologies, combined with pull-through for existing fusion systems, are expected to accelerate scoli growth over several years.

“I couldn't be more pleased with how the scoliosis business overall is performing. Certainly, timing blunted that in terms of the headline number for Q2, but the baseline of how that business is performing is probably as strong as it's ever performed.”

asked by Frederick Wise · answered by David Bailey

Was the lower set sales in Brazil due to market demand or execution challenges related to recent initiatives?

Fred Hite clarified that it was not a demand issue but a strategic decision to balance cash collections with demand. The company is prioritizing profitable revenue growth and managing the timing of set releases, especially after acquiring a distributor and focusing on improving cash collections in the region.

“I would say it's not a demand issue, it is us balancing cash collections with the demand. And so as we continue to focus on profitable revenue growth, and less focus on the lower profitable demand for sets, it's just us making the decision on when we're going to release some of those sets into the market.”

asked by Caitlin Roberts · answered by Fred Hite

What is the denominator for VerteGlide surgeon training (124 trained)? Does the math make sense for a meaningful uptick in scoli growth with modest penetration? Will these products be growth-sustaining or accelerating?

David Bailey stated that VerteGlide is early, with surgeons still identifying patients, but it will meaningfully impact growth in H2 and 2027. He sees eLLi as a potentially bigger opportunity. These complex technologies also create a 'pull-through' halo effect for existing fusion systems, setting up for accelerated scoli growth over several years.

“You pile on top of VerteGlide with eLLi. And again, eLLi is not available now, but we're making great progress. And I think eLLi is probably a bigger opportunity overall for us than VerteGlide.”

asked by Mathew Blackman · answered by David Bailey

With 45+ clinics and 20%+ growth, how is the growth algorithm shifting between same-store sales and new clinics, and does this impact durability/predictability?

David Bailey explained that growth is coming from scaling new clinics, existing clinics in less mature markets (same-store sales), and new product launches within the super cycle (e.g., DF2, modular hip brace, macu4, TRAXIO/TractorFIX). He highlighted the strong R&D team generating compelling technologies, contributing to synergies and compounding impact.

“I think what probably gets lost -- and maybe I haven't done as good a job in the past of talking about the new product launches inside the super cycle. I mean, DF2 continues to grow very, very rapidly.”

asked by Unknown Analyst · answered by David Bailey

Why is the Adjusted EBITDA target reiterated at $25M despite Q2 outperformance, and is it due to potential 7D/international sales in H2?

Fred Hite stated that the reiteration reflects conservatism to ensure they have plenty of room to deliver the numbers. He noted that the company is halfway to its $25M target ($9M in H1 vs $25M target, $5M increase YoY in H1). Potential 7D sales in H2 could put pressure on gross margin but not the overall EBITDA target.

“So I would say just more conservatism and making sure we have plenty of room to make sure we get there and deliver the numbers. The biggest reason.”

asked by Unknown Analyst · answered by Fred Hite